Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer (original) (raw)

• Hershko, A. The ubiquitin system for protein degradation and some of its roles in the control of the cell-division cycle (Nobel lecture). Angew. Chem. Int. Ed. Engl. 44, 5932–5943 (2005). An historical perspective about the discovery of the ubiquitin system that describes how E1, E2 and E3 enzymes work together to promote ubiquitin ligation to substrates.
  Article CAS PubMed Google Scholar
• Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nature Rev. Mol. Cell Biol. 6, 9–20 (2005). An excellent review of cullin RING ubiquitin ligases.
  Article CAS Google Scholar
• Cardozo, T. & Pagano, M. The SCF ubiquitin ligase: insights into a molecular machine. Nature Rev. Mol. Cell Biol. 5, 739–751 (2004).
  Article CAS Google Scholar
• Jin, J. et al. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 18, 2573–2580 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Cenciarelli, C. et al. Identification of a family of human F-box proteins. Curr. Biol. 9, 1177–1179 (1999).
  Article CAS PubMed Google Scholar
• Winston, J. T., Koepp, D. M., Zhu, C., Elledge, S. J. & Harper, J. W. A family of mammalian F-box proteins. Curr. Biol. 9, 1180–1182 (1999). References 4–6 classify the mammalian family of F-box proteins.
  Article CAS PubMed Google Scholar
• Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Rev. Cancer 8, 83–93 (2007). An excellent and up-to-date review about FBXW7 and its role in cancer.
  Article CAS Google Scholar
• Malumbres, M. & Barbacid, M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 17, 60–65 (2007).
  Article CAS PubMed Google Scholar
• Guardavaccaro, D. & Pagano, M. Stabilizers and destabilizers controlling cell cycle oscillators. Mol. Cell 22, 1–4 (2006).
  Article CAS PubMed Google Scholar
• Branzei, D. & Foiani, M. Regulation of DNA repair throughout the cell cycle. Nature Rev. Mol. Cell Biol. 9, 297–308 (2008).
  Article CAS Google Scholar
• Zhang, H., Kobayashi, R., Galaktionov, K. & Beach, D. p19Skp1 and p45Skp2 are essential elements of the cyclin A–CDK2 S phase kinase. Cell 82, 915–925 (1995).
  Article CAS PubMed Google Scholar
• Carrano, A. C., Eytan, E., Hershko, A. & Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol. 1, 193–199 (1999).
  Article CAS PubMed Google Scholar
• Sutterluty, H. et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biol. 1, 207–214 (1999).
  Article CAS PubMed Google Scholar
• Tsvetkov, L. M., Yeh, K. H., Lee, S. J., Sun, H. & Zhang, H. p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. Curr. Biol. 9, 661–664 (1999). References 12–14 characterize the function of SKP2 in cell cycle control and the ubiquitin-mediated degradation of the tumour suppressor p27.
  Article CAS PubMed Google Scholar
• Spruck, C. et al. A CDK-independent function of mammalian Cks1: targeting of SCFSkp2 to the CDK inhibitor p27Kip1. Mol. Cell 7, 639–650 (2001).
  Article CAS PubMed Google Scholar
• Ganoth, D. et al. The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27. Nature Cell Biol. 3, 321–324 (2001).
  Article CAS PubMed Google Scholar
• Bloom, J. & Pagano, M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 13, 41–47 (2003).
  Article CAS PubMed Google Scholar
• Nakayama, K. et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J. 19, 2069–2081 (2000). Shows that deletion of SKP2 results in accumulation of p27 in vivo.
  Article CAS PubMed PubMed Central Google Scholar
• Nakayama, K. et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev. Cell 6, 661–672 (2004). Shows that p27 loss reverts most of the phenotypes that are due to SKP2-deficiency and that the SKP2–p27 axis functions not only at G1–S, but also at G2–M.
  Article CAS PubMed Google Scholar
• Kossatz, U. et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18, 2602–2607 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bornstein, G. et al. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S. phase. J. Biol. Chem. 278, 25752–25757 (2003).
  Article CAS PubMed Google Scholar
• Yu, Z. K., Gervais, J. L. & Zhang, H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21CIP1/WAF1 and cyclin D proteins. Proc. Natl Acad. Sci. USA 95, 11324–11329 (1998). The first evidence that SKP2 targets p21, a tumour suppressor protein, for degradation.
  Article CAS PubMed PubMed Central Google Scholar
• Kamura, T. et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc. Natl Acad. Sci. USA 100, 10231–10236 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Hiramatsu, Y. et al. Degradation of Tob1 mediated by SCFSkp2-dependent ubiquitination. Cancer Res. 66, 8477–8483 (2006).
  Article CAS PubMed Google Scholar
• Song, M. S. et al. Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G(1)–S transition. Oncogene 10 Dec 2007 (doi:10.1038/sj.onc.1210971).
• Tedesco, D., Lukas, J. & Reed, S. I. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Genes Dev. 16, 2946–2957 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, H. et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl Acad. Sci. USA 102, 1649–1654 (2005). Identifies FOXO1 as a substrate of SKP2 and suggests SKP2-promoted proteolysis might have a role in tumorigenesis.
  Article CAS PubMed PubMed Central Google Scholar
• Tokarz, S. et al. The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase. J. Biol. Chem. 279, 46424–46430 (2004).
  Article CAS PubMed Google Scholar
• Garriga, J. et al. CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol. Cell. Biol. 23, 5165–5173 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Kiernan, R. E. et al. Interaction between cyclin T1 and SCFSKP2 targets CDK9 for ubiquitination and degradation by the proteasome. Mol. Cell. Biol. 21, 7956–7970 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Carrano, A. C. & Pagano, M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J. Cell Biol. 153, 1381–1390 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Signoretti, S. et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110, 633–641 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Waltregny, D. et al. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol. Endocrinol. 15, 765–782 (2001).
  Article CAS PubMed Google Scholar
• Lu, L., Schulz, H. & Wolf, D. A. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol. 3, 22 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Latres, E. et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl Acad. Sci. USA 98, 2515–2520 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Kang-Decker, N. et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell 5, 177–189 (2004).
  Article CAS PubMed Google Scholar
• Shim, E. H. et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res. 63, 1583–1588 (2003).
  CAS PubMed Google Scholar
• Radke, S., Pirkmaier, A. & Germain, D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene 24, 3448–3458 (2005).
  Article CAS PubMed Google Scholar
• Timmerbeul, I. et al. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc. Natl Acad. Sci. USA 103, 14009–14014 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Keller, U. B. et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 26, 2562–2574 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Philipp-Staheli, J., Payne, S. R. & Kemp, C. J. p27Kip1: regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell Res. 264, 148–168 (2001).
  Article CAS PubMed Google Scholar
• Slotky, M. et al. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res. 7, R737–R744 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Shapira, M. et al. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 103, 1336–1346 (2005).
  Article CAS PubMed Google Scholar
• Shapira, M. et al. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer 100, 1615–1621 (2004).
  Article CAS PubMed Google Scholar
• Masuda, T. A. et al. Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin. Cancer Res. 9, 5693–5698 (2003).
  CAS PubMed Google Scholar
• Hershko, D. D. & Shapira, M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer 107, 668–675 (2006).
  Article CAS PubMed Google Scholar
• Kamura, T. et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27Kip1 at G1 phase. Nature Cell Biol. 6, 1229–1235 (2004).
  Article CAS PubMed Google Scholar
• Hattori, T. et al. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. Cancer Res. 67, 10789–10795 (2007).
  Article CAS PubMed Google Scholar
• Goto, T. et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 27, 9–19 (2008).
  Article CAS PubMed Google Scholar
• Bellan, C. et al. Missing expression of pRb2/p130 in human retinoblastomas is associated with reduced apoptosis and lesser differentiation. Invest. Ophthalmol. Vis. Sci. 43, 3602–3608 (2002).
  PubMed Google Scholar
• Caputi, M. et al. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer. Clin. Cancer Res. 8, 3850–3856 (2002).
  CAS PubMed Google Scholar
• D'Andrilli, G. et al. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin. Cancer Res. 10, 3098–3103 (2004).
  Article CAS PubMed Google Scholar
• Helin, K. et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl Acad. Sci. USA 94, 6933–6938 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Scambia, G., Lovergine, S. & Masciullo, V. RB family members as predictive and prognostic factors in human cancer. Oncogene 25, 5302–5308 (2006).
  Article CAS PubMed Google Scholar
• Susini, T. et al. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J. Clin. Oncol. 16, 1085–1093 (1998).
  Article CAS PubMed Google Scholar
• Zamparelli, A. et al. Expression of cell-cycle-associated proteins pRB2/p130 and p27kip in vulvar squamous cell carcinomas. Hum. Pathol. 32, 4–9 (2001).
  Article CAS PubMed Google Scholar
• Soldatenkov, V. A., Dritschilo, A., Ronai, Z. & Fuchs, S. Y. Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis. Cancer Res. 59, 5085–5088 (1999).
  CAS PubMed Google Scholar
• Busino, L. et al. Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature 426, 87–91 (2003).
  Article CAS PubMed Google Scholar
• Tang, W. et al. Targeting β-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res. 65, 1904–1908 (2005).
  Article CAS PubMed Google Scholar
• Guardavaccaro, D. et al. Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev. Cell 4, 799–812 (2003).
  Article CAS PubMed Google Scholar
• Nakayama, K. et al. Impaired degradation of inhibitory subunit of NF-κB (IκB) and β-catenin as a result of targeted disruption of the β-TrCP1 gene. Proc. Natl Acad. Sci. USA 100, 8752–8757 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Mailand, N., Bekker-Jensen, S., Bartek, J. & Lukas, J. Destruction of Claspin by SCFβTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol. Cell 23, 307–318 (2006).
  Article CAS PubMed Google Scholar
• Peschiaroli, A. et al. SCFβTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol. Cell 23, 319–329 (2006).
  Article CAS PubMed Google Scholar
• Watanabe, N. et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc. Natl Acad. Sci. USA 101, 4419–4424 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Ougolkov, A. et al. Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer. J. Natl Cancer Inst. 96, 1161–1170 (2004).
  Article CAS PubMed Google Scholar
• Muerkoster, S. et al. Increased expression of the E3-ubiquitin ligase receptor subunit βTRCP1 relates to constitutive nuclear factor-κB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 65, 1316–1324 (2005).
  Article PubMed Google Scholar
• Koch, A. et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin. Cancer Res. 11, 4295–4304 (2005).
  Article CAS PubMed Google Scholar
• Spiegelman, V. S. et al. Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J. Biol. Chem. 277, 36624–36630 (2002).
  Article CAS PubMed Google Scholar
• Kudo, Y. et al. Role of F-box protein βTrcp1 in mammary gland development and tumorigenesis. Mol. Cell. Biol. 24, 8184–8194 (2004). Shows that β-TrCP1 positively controls the proliferation of breast epithelium and its overexpression induces transformation in the breast epithelium.
  Article CAS PubMed PubMed Central Google Scholar
• Karin, M. & Greten, F. R. NF-κB: linking inflammation and immunity to cancer development and progression. Nature Rev. Immunol. 5, 749–759 (2005).
  Article CAS Google Scholar
• Wu, C. & Ghosh, S. β-TrCP mediates the signal-induced ubiquitination of IκBβ. J. Biol. Chem. 274, 29591–29594 (1999).
  Article CAS PubMed Google Scholar
• Shirane, M., Hatakeyama, S., Hattori, K., Nakayama, K. & Nakayama, K. Common pathway for the ubiquitination of IκBα, IκBβ, and IκBε mediated by the F-box protein FWD1. J. Biol. Chem. 274, 28169–28174 (1999).
  Article CAS PubMed Google Scholar
• Tan, P. et al. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IκBα. Mol. Cell 3, 527–533 (1999). One of the first papers showing that the SCF contains the RING-finger protein RBX1 and that an SCF containing β-TrCP targets IκBα for degradation.
  Article CAS PubMed Google Scholar
• Kroll, M. et al. Inducible degradation of IkBa by the proteasome requires interaction with the F-box protein h-βTrCP. J. Biol. Chem. 274, 7941–7945 (1999).
  Article CAS PubMed Google Scholar
• Spencer, E., Jiang, J. & Chen, Z. J. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev. 13, 284–294 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Winston, J. T. et al. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 13, 270–283 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Yaron, A. et al. Identification of the receptor component of the IκBα-ubiquitin ligase. Nature 396, 590–594 (1998).
  Article CAS PubMed Google Scholar
• Hatakeyama, S. et al. Ubiquitin-dependent degradation of IκBα a is mediated by a ubiquitin ligase Skp1/Cul1/F-box protein FWD1. Proc. Natl Acad. Sci. USA 96, 3859–3863 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Arsura, M. & Cavin, L. G. Nuclear factor-κB and liver carcinogenesis. Cancer Lett. 229, 157–169 (2005).
  Article CAS PubMed Google Scholar
• Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004).
  Article CAS PubMed Google Scholar
• Dhawan, P. & Richmond, A. A novel NF-κB-inducing kinase-MAPK signaling pathway up-regulates NF-κB activity in melanoma cells. J. Biol. Chem. 277, 7920–7928 (2002).
  Article CAS PubMed Google Scholar
• Liu, J. et al. Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells. Oncogene 26, 1954–1958 (2007).
  Article CAS PubMed Google Scholar
• Yang, H. S. et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 23, 26–37 (2003).
  Article PubMed PubMed Central CAS Google Scholar
• Dorrello, N. V. et al. S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467–471 (2006).
  Article CAS PubMed Google Scholar
• Afonja, O., Juste, D., Das, S., Matsuhashi, S. & Samuels, H. H. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 23, 8135–8145 (2004).
  Article CAS PubMed Google Scholar
• Goke, R., Barth, P., Schmidt, A., Samans, B. & Lankat-Buttgereit, B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1. Am. J. Physiol. Cell Physiol. 287, C1541–C1546 (2004).
  Article CAS PubMed Google Scholar
• Wen, Y. H. et al. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol. Rep. 18, 1387–1393 (2007).
  CAS PubMed Google Scholar
• Zhang, H. et al. Involvement of programmed cell death 4 in transforming growth factor-β1-induced apoptosis in human hepatocellular carcinoma. Oncogene 25, 6101–6112 (2006).
  Article CAS PubMed Google Scholar
• Mudduluru, G. et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 110, 1697–1707 (2007).
  Article CAS PubMed Google Scholar
• Chen, Y. et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J. Pathol. 200, 640–646 (2003).
  Article CAS PubMed Google Scholar
• Majumder, S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 5, 1929–1935 (2006).
  Article CAS PubMed Google Scholar
• Westbrook, T. F. et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837–848 (2005).
  Article CAS PubMed Google Scholar
• Westbrook, T. F. et al. SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452, 370–374 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Saitoh, T. & Katoh, M. Expression profiles of βTRCP1 and βTRCP2, and mutation analysis of βTRCP2 in gastric cancer. Int. J. Oncol. 18, 959–964 (2001).
  CAS PubMed Google Scholar
• Kim, C. J. et al. Somatic mutations of the β-TrCP gene in gastric cancer. Apmis 115, 127–133 (2007).
  Article CAS PubMed Google Scholar
• Gerstein, A. V. et al. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 34, 9–16 (2002).
  Article CAS PubMed Google Scholar
• Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).
  Article CAS PubMed Google Scholar
• Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469–480 (2006).
  Article CAS PubMed Google Scholar
• Liu, C. et al. β-Trcp couples β-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc. Natl Acad. Sci. USA 96, 6273–6278 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Kitagawa, M. et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J. 18, 2401–2410 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Lagna, G., Carnevali, F., Marchioni, M. & Hemmati-Brivanlou, A. Negative regulation of axis formation and Wnt signaling in Xenopus embryos by the F-box/WD40 protein βTrCP. Mech. Dev. 80, 101–106 (1999).
  Article CAS PubMed Google Scholar
• Hart, M. et al. The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell. Curr. Biol. 9, 207–210 (1999).
  Article CAS PubMed Google Scholar
• Latres, E., Chiaur, D. S. & Pagano, M. The human F box protein β-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-catenin. Oncogene 18, 849–854 (1999).
  Article CAS PubMed Google Scholar
• Marikawa, Y. & Elinson, R. P. β-TrCP is a negative regulator of Wnt/β-catenin signaling pathway and dorsal axis formation in Xenopus embryos. Mech. Dev. 77, 75–80 (1998).
  Article CAS PubMed Google Scholar
• Li, Y. et al. Stabilization of prolactin receptor in breast cancer cells. Oncogene 25, 1896–1902 (2006).
  Article CAS PubMed Google Scholar
• Guardavaccaro, D. et al. Control of chromosome stability by the β-TrCP–REST–Mad2 axis. Nature 452, 365–369 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Fuller, G. N. et al. Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol. Cancer Ther. 4, 343–349 (2005).
  CAS PubMed Google Scholar
• Su, X., Kameoka, S., Lentz, S. & Majumder, S. Activation of REST/NRSF target genes in neural stem cells is sufficient to cause neuronal differentiation. Mol. Cell. Biol. 24, 8018–8025 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Lawinger, P. et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nature Med. 6, 826–831 (2000).
  Article CAS PubMed Google Scholar
• Kanemori, Y., Uto, K. & Sagata, N. β-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl Acad. Sci. USA 102, 6279–6284 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Boutros, R., Lobjois, V. & Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature Rev. Cancer 7, 495–507 (2007).
  Article CAS Google Scholar
• Cangi, M. G. et al. Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest. 106, 753–761 (2000).
  Article CAS Google Scholar
• Kristjansdottir, K. & Rudolph, J. Cdc25 phosphatases and cancer. Chem. Biol. 11, 1043–1051 (2004).
  Article CAS PubMed Google Scholar
• Hernandez, S. et al. Cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas. Cancer Res. 58, 1762–1767 (1998).
  CAS PubMed Google Scholar
• Hernandez, S. et al. Cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. Int. J. Cancer 89, 148–152 (2000).
  Article CAS PubMed Google Scholar
• Ito, Y. et al. Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation. Int. J. Mol. Med. 13, 431–435 (2004).
  CAS PubMed Google Scholar
• Loffler, H. et al. Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene 22, 8063–8071 (2003).
  Article PubMed CAS Google Scholar
• Hsu, J. Y., Reimann, J. D., Sorensen, C. S., Lukas, J. & Jackson, P. K. E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APCCdh1. Nature Cell Biol. 4, 358–366 (2002).
  Article CAS PubMed Google Scholar
• Gutgemann, I., Lehman, N. L., Jackson, P. K. & Longacre, T. A. Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod. Pathol. 21, 445–454 (2008).
  Article PubMed CAS Google Scholar
• Lehman, N. L. et al. Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am. J. Pathol. 170, 1793–1805 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Adams, J. & Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304–311 (2004).
  Article CAS PubMed Google Scholar
• Busino, L. et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316, 900–904 (2007).
  Article CAS PubMed Google Scholar
• Gallego, M. & Virshup, D. M. Post-translational modifications regulate the ticking of the circadian clock. Nature Rev. Mol. Cell Biol. 8, 139–148 (2007).
  Article CAS Google Scholar
• Frescas, D., Guardavaccaro, D., Bassermann, F., Koyama-Nasu, R. & Pagano, M. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature 450, 309–313 (2007).
  Article CAS PubMed Google Scholar
• Bassermann, F. et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45–57 (2005).
  Article CAS PubMed Google Scholar
• Amador, V., Ge, S., Santamaria, P. G., Guardavaccaro, D. & Pagano, M. APC/CCdc20 controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol. Cell 27, 462–473 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Li, X., Zhao, Q., Liao, R., Sun, P. & Wu, X. The SCFSkp2 ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J. Biol. Chem. 278, 30854–30858 (2003).
  Article CAS PubMed Google Scholar
• Mendez, J. et al. Human origin recognition complex large subunit is degraded by ubiquitin-mediated proteolysis after initiation of DNA replication. Mol. Cell 9, 481–491 (2002).
  Article CAS PubMed Google Scholar
• Moro, L., Arbini, A. A., Marra, E. & Greco, M. Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation. J. Biol. Chem. 281, 22100–22107 (2006).
  Article CAS PubMed Google Scholar
• Jiang, H. et al. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J. recombinase to the cell cycle. Mol. Cell 18, 699–709 (2005).
  Article CAS PubMed Google Scholar
• Liu, Y. et al. The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol. Cell. Biol. 26, 3114–3123 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, H., Cheng, E. H. & Hsieh, J. J. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev. 21, 2385–2398 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Charrasse, S., Carena, I., Brondani, V., Klempnauer, K. H. & Ferrari, S. Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCFp45Skp2 pathway. Oncogene 19, 2986–2995 (2000).
  Article CAS PubMed Google Scholar
• von der Lehr, N., Johansson, S. & Larsson, L. G. Implication of the ubiquitin/proteasome system in Myc-regulated transcription. Cell Cycle 2, 403–407 (2003).
  CAS PubMed Google Scholar
• von der Lehr, N. et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol. Cell 11, 1189–1200 (2003).
  Article CAS PubMed Google Scholar
• Marti, A., Wirbelauer, C., Scheffner, M. & Krek, W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nature Cell Biol. 1, 14–19 (1999).
  Article CAS PubMed Google Scholar
• Oh, K. J. et al. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J. Virol. 78, 5338–5346 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, Y. W. & Yang, J. L. Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling. J. Biol. Chem. 281, 915–926 (2006).
  Article CAS PubMed Google Scholar
• Liang, M. et al. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2. Mol. Cell. Biol. 24, 7524–7537 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, Z., Nie, L., Xu, M. & Sun, X. H. Notch-induced E2A degradation requires CHIP and Hsc70 as novel facilitators of ubiquitination. Mol. Cell. Biol. 24, 8951–8962 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Nie, L., Xu, M., Vladimirova, A. & Sun, X. H. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J. 22, 5780–5792 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Nie, L., Wu, H. & Sun, X. H. Ubiquitination and degradation of Tal1/SCL is induced by Notch signaling and depends on Skp2 and CHIP. J. Biol. Chem. (2007).
• Sanada, T. et al. Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci. 95, 969–976 (2004).
  Article CAS PubMed Google Scholar
• Traub, F., Mengel, M., Luck, H. J., Kreipe, H. H. & von Wasielewski, R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res. Treat 99, 185–191 (2006).
  Article CAS PubMed Google Scholar
• Sonoda, H. et al. Significance of skp2 expression in primary breast cancer. Clin. Cancer Res. 12, 1215–1220 (2006).
  Article CAS PubMed Google Scholar
• Narayan, G. et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 46, 373–384 (2007).
  Article CAS PubMed Google Scholar
• Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA 98, 5043–5048 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Nishida, N., Nagasaka, T., Kashiwagi, K., Boland, C. R. & Goel, A. High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol. Ther. 6, 525–533 (2007).
  Article CAS PubMed Google Scholar
• Kamata, Y. et al. High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. J. Cancer Res. Clin. Oncol. 131, 591–596 (2005).
  Article CAS PubMed Google Scholar
• Lahav-Baratz, S. et al. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. Mol. Hum. Reprod. 10, 567–572 (2004).
  Article CAS PubMed Google Scholar
• Ma, X. M., Liu, J. H., Guo, J. W., Liu, Y. & Zuo, L. F. Correlation of Skp2 expression in gastric carcinoma to expression of P27 and PTEN. Ai Zheng 25, 56–61 (2006).
  CAS PubMed Google Scholar
• Ma, X. M., Liu, Y., Guo, J. W., Liu, J. H. & Zuo, L. F. Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World J. Gastroenterol. 11, 6716–6721 (2005).
  Article PubMed PubMed Central Google Scholar
• Schiffer, D., Cavalla, P., Fiano, V., Ghimenti, C. & Piva, R. Inverse relationship between p27/Kip1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and western blot. Neurosci. Lett. 328, 125–128 (2002).
  Article CAS PubMed Google Scholar
• Saigusa, K. et al. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci. 96, 676–683 (2005).
  Article CAS PubMed Google Scholar
• Penin, R. M. et al. Over-expression of p45SKP2 in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27KIP1 down-regulation. Mod. Pathol. 15, 1227–1235 (2002).
  Article CAS PubMed Google Scholar
• Inui, N. et al. High expression of Cks1 in human non-small cell lung carcinomas. Biochem. Biophys. Res. Commun. 303, 978–984 (2003).
  Article CAS PubMed Google Scholar
• Yokoi, S. et al. Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes. Am. J. Pathol. 165, 175–180 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, C. Q. et al. Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin. Cancer Res. 10, 1984–1991 (2004).
  Article CAS PubMed Google Scholar
• Coe, B. P. et al. High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. Genes Chromosomes Cancer 42, 308–313 (2005).
  Article CAS PubMed Google Scholar
• Zhan, F. et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 109, 4995–5001 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Shaughnessy, J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10, S117–S126 (2005).
  Article CAS Google Scholar
• Woenckhaus, C. et al. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol. Histopathol 20, 501–508 (2005).
  CAS PubMed Google Scholar
• Li, Q., Murphy, M., Ross, J., Sheehan, C. & Carlson, J. A. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J. Cutan Pathol. 31, 633–642 (2004).
  Article PubMed Google Scholar
• Katagiri, Y., Hozumi, Y. & Kondo, S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J. Dermatol. Sci. 42, 215–224 (2006).
  Article CAS PubMed Google Scholar
• Bhatt, K. V., Hu, R., Spofford, L. S. & Aplin, A. E. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 26, 1056–1066 (2007).
  Article CAS PubMed Google Scholar
• Fukuchi, M. et al. Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma. Anticancer Res. 24, 777–783 (2004).
  CAS PubMed Google Scholar
• Harada, K. et al. High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Anticancer Res. 25, 2471–2475 (2005).
  CAS PubMed Google Scholar
• Kudo, Y. et al. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 61, 7044–7047 (2001).
  CAS PubMed Google Scholar
• Kitajima, S. et al. Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation. Am. J. Pathol. 165, 2147–2155 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Shigemasa, K., Gu, L., O'Brien, T. J. & Ohama, K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin. Cancer Res. 9, 1756–1763 (2003).
  CAS PubMed Google Scholar
• Sui, L. et al. Clinical significance of Skp2 expression, alone and combined with Jab1 and p27 in epithelial ovarian tumors. Oncol. Rep. 15, 765–771 (2006).
  CAS PubMed Google Scholar
• Drobnjak, M. et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin. Cancer Res. 9, 2613–2619 (2003).
  CAS PubMed Google Scholar
• Yang, G. et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. 8, 3419–3426 (2002).
  CAS PubMed Google Scholar
• Amir, R. E., Haecker, H., Karin, M. & Ciechanover, A. Mechanism of processing of the NF-κB2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCFβ-TrCP ubiquitin ligase. Oncogene 23, 2540–2547 (2004).
  Article CAS PubMed Google Scholar
• Fong, A. & Sun, S. C. Genetic evidence for the essential role of β-transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J. Biol. Chem. 277, 22111–22114 (2002).
  Article CAS PubMed Google Scholar
• Lang, V. et al. βTrCP-mediated proteolysis of NF-κB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol. Cell. Biol. 23, 402–413 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Orian, A. et al. SCFβ-TrCP ubiquitin ligase-mediated processing of NF-κB p105 requires phosphorylation of its C-terminus by IκB kinase. EMBO J. 19, 2580–2591 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Lassot, I. et al. ATF4 degradation relies on a phosphorylation-dependent interaction with the SCFβTrCP ubiquitin ligase. Mol. Cell. Biol. 21, 2192–2202 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Li, Y., Kumar, K. G., Tang, W., Spiegelman, V. S. & Fuchs, S. Y. Negative regulation of prolactin receptor stability and signaling mediated by SCFβ-TrC E3 ubiquitin ligase. Mol. Cell. Biol. 24, 4038–4048 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Besnard-Guerin, C. et al. HIV-1 Vpu sequesters β-transducin repeat-containing protein (βTrCP) in the cytoplasm and provokes the accumulation of β-catenin and other SCFβTrCP substrates. J. Biol. Chem. 279, 788–795 (2004).
  Article CAS PubMed Google Scholar
• Kumar, K. G., Krolewski, J. J. & Fuchs, S. Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J. Biol. Chem. 279, 46614–46620 (2004).
  Article CAS PubMed Google Scholar
• Mantovani, F. & Banks, L. Regulation of the discs large tumor suppressor by a phosphorylation-dependent interaction with the β-TrCP ubiquitin ligase receptor. J. Biol. Chem. 278, 42477–42486 (2003).
  Article CAS PubMed Google Scholar
• Reischl, S. et al. β-TrCP1-mediated degradation of PERIOD2 is essential for circadian dynamics. J. Biol. Rhythms 22, 375–386 (2007).
  Article CAS PubMed Google Scholar
• Shirogane, T., Jin, J., Ang, X. L. & Harper, J. W. SCFβ-TRCP controls clock-dependent transcription via casein kinase 1-dependent degradation of the mammalian period-1 (Per1) protein. J. Biol. Chem. 280, 26863–26872 (2005).
  Article CAS PubMed Google Scholar
• Eide, E. J. et al. Control of mammalian circadian rhythm by CKIε-regulated proteasome-mediated PER2 degradation. Mol. Cell. Biol. 25, 2795–2807 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Tian, Y. et al. TAZ promotes PC2 degradation through a SCFβ-Trcp E3 ligase complex. Mol. Cell. Biol. 27, 6383–6395 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ding, Q. et al. Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 27, 4006–4017 (2007).
  Article CAS PubMed Google Scholar
• Tan, P. et al. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IκBα. Mol. Cell 3, 527–533 (1999).
  Article CAS PubMed Google Scholar
• Gallegos, J. R. et al. SCF TrCP1 activates and ubiquitylates TAp63γ. J. Biol. Chem. 283, 66–75 (2008).
  Article CAS PubMed Google Scholar
• van Kerkhof, P., Putters, J. & Strous, G. J. The ubiquitin ligase SCFβTrCP regulates the degradation of the growth hormone receptor. J. Biol. Chem. 282, 20475–20483 (2007).
  Article CAS PubMed Google Scholar
• Seki, A. et al. Plk1- and β-TrCP-dependent degradation of Bora controls mitotic progression. J. Cell Biol. 181, 65–78 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Soond, S. M. et al. ERK and the E3 ubiquitin ligase βTRCP targets STAT1 for degradation. J. Biol. Chem. (2008).